创伤后氨甲环酸给药时机与死亡率影响
本研究为PATCH-Trauma试验的探索性分析,纳入成人严重创伤且疑似创伤诱导凝血病的患者,随机接受氨甲环酸(院前1 g静脉弹丸式注射,到院后1 g输注8小时)或匹配安慰剂。意向性治疗队列共1287例(安慰剂组635例,氨甲环酸组652例),伤后至首剂中位时间79分钟(IQR 55-112)。伤后90分钟内给药显著降低28天死亡风险(氨甲环酸组67/393[17%] vs 安慰剂组91/363[25%],调整RR 0.64,95%CI 0.50-0.82),超过90分钟给药未降低28天死亡率(调整RR 1.04,95%CI 0.74-1.47)。结论提示氨甲环酸最佳治疗窗口可能为伤后90分钟内。
要点
- 伤后90分钟内给予氨甲环酸显著降低28天死亡风险:氨甲环酸组67/393(17%)vs 安慰剂组91/363(25%),调整RR 0.64(95%CI 0.50-0.82)。
- 伤后超过90分钟给予氨甲环酸未降低28天死亡率:调整RR 1.04(95%CI 0.74-1.47),95%CI上限跨过等效线(RR=1)。
- 随着伤后至首剂时间延长,28天死亡风险增加,获益在90分钟内最为明显。
- PATCH-Trauma方案:成人严重创伤疑似创伤诱导凝血病,院前氨甲环酸1 g静脉弹丸式注射,到院后1 g输注8小时。
- 伤后至首剂中位时间79分钟(IQR 55-112),提示院前早期给药可行。
适用人群与场景
- 成人严重创伤且疑似创伤诱导凝血病患者,纳入PATCH-Trauma试验。
处置流程与药物剂量
- 氨甲环酸组:院前静脉弹丸式注射1 g,到院后1 g输注8小时。
- 安慰剂组:匹配安慰剂。
研究设计与关键结果
- 研究类型:PATCH-Trauma试验的探索性分析,意向性治疗队列1287例(安慰剂组635例,氨甲环酸组652例)。
- 伤后至首剂中位时间79分钟(IQR 55-112)。
- 伤后90分钟内给药:氨甲环酸组67/393(17%)vs 安慰剂组91/363(25%),调整RR 0.64(95%CI 0.50-0.82),显著降低28天死亡风险。
- 伤后超过90分钟给药:调整RR 1.04(95%CI 0.74-1.47),未降低28天死亡率,95%CI上限跨过等效线(RR=1)。
- 随着伤后至首剂时间延长,28天死亡风险增加,获益在90分钟内最明显。
证据类型、等级与局限
- 证据类型:PATCH-Trauma随机对照试验的探索性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为创伤后氨甲环酸最佳治疗窗口可能在伤后90分钟内,支持在严重创伤疑似凝血病患者中于伤后90分钟内启动氨甲环酸治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: Trauma resuscitation guidelines across the world have incorporated the administration of tranexamic acid (TXA) within 3 hours of injury. The 3-hour window was deduced from the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2) trial and has not been replicated. The aim of this study was to determine whether death within 28 days after trauma varied according to time from injury to the first TXA dose and, if so, precisely determine the therapeutic window.
METHODS: This was an exploratory analysis of the Prehospital Tranexamic Acid for Severe Trauma (PATCH-Trauma) trial, which enrolled adults with major trauma and suspected trauma-induced coagulopathy. Eligible patients were randomized to receive either TXA (administered intravenously as a bolus dose of 1 g before hospital admission, followed by a 1 g infusion over a period of 8 hours after arrival at the hospital) or matched placebo. In this analysis, we examined the effect of time from injury to first treatment dose on death within 28 days utilizing a continuous scale with linear, first-degree fractional polynomial, and second-degree fractional polynomial functions of time from injury to first treatment dose. Further log-binomial regression analyses were performed in subgroups based on the information obtained from the previous step.
RESULTS: The intention-to-treat study cohort comprised 1,287 patients, of which 635 had been allocated to the placebo arm and 652 to the TXA arm. The median time from injury to first treatment dose was 79 (interquartile range [IQR] 55 to 112) minutes. Risk of death within 28 days increased as the time to first dose of treatment increased, with benefit most pronounced up to 90 minutes. Beyond 90 minutes, the upper 95% confidence interval (CI) crossed the line of equivalence (risk ratio, 1). Administration of TXA within 90 minutes significantly reduced the risk of death within 28 days (67/393 [17%] in the TXA group versus 91/363 [25%] in placebo group; adjusted risk ratio 0.64, 95% CI 0.50 to 0.82), whereas administration beyond 90 minutes did not decrease mortality at 28 days (adjusted risk ratio 1.04, 95% CI 0.74 to 1.47).
CONCLUSION: The optimal therapeutic window for TXA after trauma may be within 90 minutes.
参考来源
- Ali A, Gruen RL, Bernard SA, et al. Tranexamic Acid Timing and Mortality Impact After Trauma. Ann Emerg Med. 2025. PMID: 40751727. doi:10.1016/j.annemergmed.2025.06.609
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。